Josh Gottheimer (D-NJ)

Leo’s Law

H.R. 7693 · House bill Health

A Democratic bill with 1 Republican cosponsor · See the cosponsor

Last activity — Referred to the House Committee on Energy and Commerce.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

This bill, known as "Leo's Law," aims to reduce the impact of the COVID-19 pandemic on incentives for developing orphan drugs. It extends several exclusivity periods and patent-related approval-delay periods by 180 days for "covered orphan drugs." To qualify, the drug must have had an application submitted during the COVID-19 emergency period and have no approved indications other than for rare diseases or conditions.

Yes· 3 of 6

  • Scored +5

    Would business owners be better off under this?

    Specifically benefits pharmaceutical company owners by extending market exclusivity.

  • Scored +5

    Would people with disabilities be better off under this?

    Many rare disease patients fall into this category and may benefit from increased drug development.

  • Scored +4

    Does this make health care easier to get in general?

    Increases incentives for pharmaceutical companies to develop and maintain treatments for rare diseases.

The opposite· 3 of 4

  • Scored -3

    Does this lower the price of prescription medicines?

    Extended exclusivity periods for orphan drugs prevent generic competition, potentially keeping drug prices higher for longer.

  • Scored -2

    Would households on low incomes be better off under this?

    Potential for higher drug costs due to delayed generic entry.

  • Scored -2

    Does this give people more protection from unfair business practices?

    Extending exclusivity periods may delay access to lower-cost generic alternatives for consumers.